Biocept expands breast cancer offering Biocept announced the launch of its estrogen receptor status testing on CTCs that will be performed at the Company's CLIA-certified and CAP-accredited laboratory. The launch of ER status testing, in conjunction with the company's HER2 receptor status test, will offer health care providers an additional testing option when a tumor biopsy is unavailable or unsafe. For patients with recurring or newly diagnosed metastatic breast cancer, accurate identification of hormone and HER2 receptors status plays a major role in treatment outcomes. The company said, "Our validation study for hormone status provided significant insights into hormone status as it relates to primary and metastatic breast cancers. We were able to correlate both concordance and discordance of primary biopsy tissue and metastatic biopsy tissue with the CTC status of estrogen receptors."